 Immune Checkpoint Modulators ICMs are associated with significant adverse events. Currently there are no validated patient reported outcome PRO tools to assess health related quality of life HRQOL specifically in patients receiving ICMs. HRQOL is a multidimensional concept of a patients perceived well-being that can be affected by disease and treatment. There is an urgent need to assess the impact of ICMs on HRQOL, to better understand the balance between efficacy and toxicity with these agents. 